A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease
This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach[1].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options[2].
| Parameter | Value |
|---|---|
| NCT Number | NCT06947941 |
| Phase | PHASE3 |
| Status | NOT_YET_RECRUITING |
| Sponsor | Bristol-Myers Squibb |
| Enrollment | 1046 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2025-07-31 00:00:00 |
| Completion Date | 2027-10-25 00:00:00 |
| Last Updated | 2025-04-27 00:00:00 |
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[2:1].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[3].
The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[4].
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[5].
Key features of the Phase 3 design include:
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[6].
KarXT (xanomeline-trospium) represents a fundamentally different approach to psychosis treatment. Unlike traditional antipsychotics that primarily block dopamine D2 receptors, KarXT works through muscarinic acetylcholine receptor modulation:
Xanomeline Component:
Trospium Component:
This mechanism is particularly relevant for AD psychosis because:
Psychosis affects approximately 40-60% of Alzheimer's disease patients, manifesting as:
Current treatment options are severely limited:
| Treatment | Efficacy | Key Limitations |
|---|---|---|
| Risperidone | Moderate | Extrapyramidal symptoms, stroke risk |
| Quetiapine | Limited | Sedation, metabolic effects |
| Pimavanserin | Moderate (PD psychosis) | Limited AD data, QT prolongation |
| Aripiprazole | Limited | Mixed results in AD |
No FDA-approved treatment specifically for AD psychosis exists. This represents a critical gap in care.
The cholinergic system plays a crucial role in both cognitive and psychiatric manifestations of AD:
KarXT exploits this preserved receptor infrastructure by providing direct agonism, potentially bypassing the depleted endogenous neurotransmitter.
The ADEPT-5 (Alzheimer's Disease Psychosis Treatment-5) trial enrolls participants with:
Inclusion:
Exclusion:
KarXT is administered as:
The placebo arm receives matching inactive formulation.
NPI-C: Hallucinations and Delusions (NPI-C: H+D):
Muscarinic acetylcholine receptors (mAChRs) are G-protein-coupled receptors with five subtypes (M1-M5):
M1 Receptors:
M4 Receptors:
Xanomeline's dual M1/M4 agonism addresses:
Xanomeline demonstrated:
Previous clinical trials in AD showed:
| Trial | Agent | Phase | Status | Key Finding |
|---|---|---|---|---|
| HARMONY | Pimavanserin | Phase 3 | Positive | Reduced psychosis in AD |
| ADEPT-1 | KarXT | Phase 2 | Positive | NPI improvement |
| ADEPT-3 | KarXT | Phase 3 | Ongoing | Confirmatory trial |
| NCT04437511 | Nabilone | Phase 2 | Recruiting | Cannabinoid approach |
KarXT's dual mechanism (M1/M4 agonism + peripheral trospium) differs from:
KarXT offers potential safety advantages over traditional antipsychotics:
| Risk | Typical Antipsychotics | KarXT |
|---|---|---|
| Extrapyramidal symptoms | High | Low |
| Sedation | Moderate | Moderate |
| Weight gain | High | Minimal |
| Metabolic effects | High | Minimal |
| Stroke risk (elderly) | Elevated | Not observed |
The absence of D2 receptor antagonism suggests:
KarXT received Breakthrough Therapy designation from FDA for:
KarXT (marketed as Cozavan in some regions) is currently:
If ADEPT-5 is successful:
Novel therapeutic approaches for neurodegenerative diseases (2024). 2024. ↩︎
[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23). 2023. ↩︎ ↩︎
Amyloid cascade hypothesis: time for a reappraisal (2023). 2023. ↩︎
Mechanism-driven clinical trials in neurodegeneration (2024). 2024. ↩︎
Clinical trial design in neurodegenerative disease (2023). 2023. ↩︎
Future of Alzheimer's disease clinical trials (2024). 2024. ↩︎